ACR21 Best Abstracts - Day 2

Jack Cush, MD

Nov 07, 2021 8:53 pm

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy given by SQ injx; it's presented by LN-DCs causing: CTL exhaustion while controlling autoreactive CD4+ T cells. Abstract #0967
VITAL RCT of Omega-3 and Vit D in preventing autoimmune diseases in 25,871 individuals. They both work! Reducing incident autoimmune disease by 25-30%. Abstract# 0957
#COVID vaccine in #SLE doesn’t cause #lupus flares, does not increase in APS. What about #SARS-CoV2 infection in SLE. No increase in Flares, but increase in APS Abs; from Hopkins cohort and Dr. Petri abstract# 0858
How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1/2 w RA & 15% w #SLE. New risks Asian with pericentral pattern and overall. Length of time on use and Upwards arrowwt based dose per day & CKD all risks. Abstract# 0989
Keep the Hydroxychloroquine! SLICC cohort eval flare risk in 1460 pts who decrease or d/c HCQ: Patients in remission who d/c HCQ flared HR 2.77 (1.46,5.26) and those who decreased HCQ dose flared HR 2.14 (1.34, 3.42). Abstract# 0959
What to do if pt on a TNFi develops cancer? Can you safely restart TNFi later? Depends on cancer, timing - how long ago was cancer, Rx and patient preference. Data diff from RABBIT registry vs British bio registry. Session 7S413
Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts: Older age, Male, Areas outside Europe, USA, Canada, Infection before June 2020, Any Corticosteroid dose, not on therapy, Rituximab, comorbidities and disease activity. Abstract# 0866
US veterans with rheumatoid arthritis followed for 17 yrs, several cytokines and chemokines associated with a higher risk of incident MACE independent of typical CVD, RF & RA activity. MACE occurs even if in LDA/remission. Abstract# 0572
COVID-19 outcomes in vasculitis and PMR; High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes. Abstract# 0952
Nationwide claims study showed increased occurrence of multimorbidity in men with SLE compared to women with SLE. Abstract# 0579
"The strongest single predictor of both telemedicine and electronic patient portal use was English language preference." Improving access needs to include barrier awareness of SES and communication issues. Abstract# 0615
Comorbidity burden can affect treatment of Inflammatory Arthritis. Higher comorbidity burden patients are more likely to receive steroids than TNFis; Suboptimal therapy? Abstract# 0577
Microbiome evaluation of monozygotic twins discordant for Psoriasis reveals Ruminococcus bromii species significantly reduced & two pathways related to tetrahydrofolate biosynthesis upregulated in PSO twins compared to their unaffected siblings (p< 0.05). Abstract# 0944
Study of TNF vs non-TNFi treatment in obese RA pts. TNFi use improves disease activity compared with ABA in obese pts. In non-obese patients, TNFi use improveds disease activity compared to TCZ use. Abstract# 0588
There’s an argument against HCQ dosing <5mg/kg from cardiac perspective in #lupus. A retrospective study N=296 pts, 13% developed CV events. There was a 28% lower risk (CHF, arrhythmia/cardiac death) per mg/kg of HCQ in non-smokers. Abstract# 0871